REFERENCES
1. De las Peñas R, Escobar Y, Henao F, Blasco A, Rodríguez CA. SEOM guidelines on hydroelectrolytic disorders. Clin Transl Oncol 2014;16:1051-9.
2. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126:S1-42.
3. Marquina G, Runkle I, Manzano A, Granja M, Aguado C, et al. Incidence, classification and diagnosis of hypo- natremia in patients admitted to the oncology ward. J Clin Oncol 2015;33:e20656.
4. Castillo JJ, Glezerman IG, Boklage SH, Chiodo J, Tidwell BA, et al. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer 2016;16:564.
5. Berardi R, Rinaldi S, Caramanti M, Grohè C, Santoni M, et al. Hyponatremia in cancer patients: time for a new approach. Crit Rev Oncol Hematol 2016;102:15-25.
6. Zylberman M, Couselo FAD. Incidencia y mortalidad de la hiponatremia en pacientes con cáncer. Diálisis Traspl 2010;10.
7. Djamgoz MBA, Fraser SP, Brackenbury WJ. In vivo evidence for voltage-gated sodium channel expression in carcinomas and potentiation of metastasis. Cancers 2019;11:1675.
8. Berardi R, Santoni M, Rinaldi S, Nunzi E, Smerilli A, et al. Risk of hyponatraemia in cancer patients treated with targeted therapies: a systematic review and meta-analysis of clinical trials. PLoS One 2016;11:e0152079.
9. Bengus A, Babiuc RD. Hyponatremia - predictor of adverse prognosis in cirrhosis. J Med Life 2012;5:176-8.
10. Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis 2012;59:222-8.
11. Abu Zeinah GF, Al-Kindi SG, Hassan AA, Allam A. Hyponatraemia in cancer: association with type of cancer and mortality: hyponatraemia and cancer mortality. Eur J Cancer Care (Engl) 2015;24:224-31.
12. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist 2012;17:756-65.
13. Hiponatremia en oncología. Nefrología [Internet]. 2011. Available from: http://doi.org/10.3265/NefrologiaSuplementoExtraordinario.pre2011.Sep.11149.
14. Peri A. Prognostic and predictive role of hyponatremia in cancer patients. J Cancer Metastasis Treat 2019;5:40.
15. Ball SG, Iqbal Z. Diagnosis and treatment of hyponatraemia. Best Pract Res Clin Endocrinol Metab 2016;30:161-73.
16. Aylwin S, Burst V, Peri A, Runkle I, Thatcher N. ‘Dos and don’ts’ in the management of hyponatremia. Curr Med Res Opin 2015;31:1755-61.
17. Tzoulis P, Runkle-De la Vega I. The diagnostic approach to the patient with hyponatremia: are the correct investigations being done? In: Peri A, Thompson CJ, Verbalis JG, editors. Frontiers of Hormone Research. S. Karger AG; 2019. pp. 190-9.
18. Ploutarchos T, Runkle I. Hyponatraemia in clinical practice: are we investigating and treating appropriately? In Disorders of fluid and electrolyte metabolism. FOCUS: Hyponatremia. Hormone Research 2019. Frontiers of Hormone Research 2019;52:190-199.
19. Runkle I, Chafer J. El diagnóstico diferencial de la hiponatremia. In: Gomez-Hoyos E, Runkle I, editors. Manual Enigmas de la Hiponatremia. Barcelona: Permanyer; 2018. pp. 11-13.
20. Petereit C, Zaba O, Teber I, Lüders H, Grohé C. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med 2013;13:55.
22. Runkle I, Gomez-Hoyos E, Cuesta-Hernández M, Chafer-Vilaplana J, de Miguel P. Hyponatraemia in older patients: a clinical and practical approach. Rev Clin Gerontol 2015;25:31-52.
23. Furst H, Hallows KR, Post J, Chen S, Kotzker W, et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 2000;319:240-4.
24. Johansson P, van der Wal MH, Strömberg A, Waldréus N, Jaarsma T. Fluid restriction in patients with heart failure: how should we think? Eur J Cardiovasc Nurs 2016;15:301-4.
25. Pose A, Almenar L, Manzano L, Gavira JJ, López Granados A, et al. Hyponatraemia and congestive heart failure refractory to diuretic treatment. Utility of tolvaptan. Rev Clin Esp 2017;217:398-404.
26. Schrier RW, Berl T, Orlandi C. Tolvaptan, a selective oral vasopressin v2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-112.
27. Verbalis JG, Adler S, Schrier RW, Berl T, Zhao Q, et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011;164:725-32.
28. Berardi R, Antonuzzo A, Blasi L, Buosi R, Lorusso V, et al. Practical issues for the management of hyponatremia in oncology. Endocrine 2018;61:158-64.
29. Escobar AY, Henao CF, de las Penas Bataller R, Rodríguez CA. Algoritmo de tratamiento de la hiponatremia asociada al SIADH en el paciente oncológico. Sociedad Española de Oncología Meédica 2014. Available from: http://www.seom.org/es/publicaciones/publicacionesseom/104548-algoritmo-seomdel-manejo-de-la-hi-ponatremiaen-el-paciente-oncologico [Last accessed on 21 Feb 2020].
